The startup develops a portable inhalation device that enables patients to self-administer inert gases for inhalation-based treatments targeting neurological, psychiatric, and developmental disorders. This technology addresses the need for effective therapeutic options in the management of psychiatric and neurodegenerative diseases.
Funding
$510K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many neurological, psychiatric, and developmental disorders lack effective therapeutic options, creating a significant unmet need for patients. Current treatment methods may not provide sufficient relief or may be limited by tolerability issues and systemic side effects. Precise and controlled delivery of therapeutic agents to the central nervous system remains a challenge.
Solution
Nobilis Therapeutics is developing inhalation-based therapeutics using controlled self-administration of inert gases to address unmet medical needs in psychiatric and neurodegenerative diseases. The company's approach combines proprietary gas mixtures with the Zephyrus™ device, a portable inhalation system designed for reproducible, standardized, and controlled patient exposure. The Zephyrus™ device incorporates intelligent electronic safeguards to prevent accidental oversupply and cloud-based capabilities for remote monitoring of patient compliance and dosage adjustment. By leveraging data from over 2500 patients successfully treated for conditions ranging from panic disorder to autoimmune diseases, Nobilis aims to offer a safe and effective therapeutic option. The company is currently advancing its technologies into human clinical trials.
Target Audience
The primary target audience includes patients suffering from psychiatric and neurodegenerative diseases, as well as physicians and healthcare providers seeking innovative therapeutic options for these conditions.
Features
- Proprietary Zephyrus™ inhalation device designed for self-administration of NBTX-001 (inert gas mixture).
- Intelligent electronic safeguards to prevent accidental oversupply of the drug.
- Cloud-based capabilities for remote monitoring of patient compliance.
- Remote adjustment of dosing regimens.
- Portable and lightweight design for patient convenience.